Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 16/20 | 0.69 |
| ▸ | ITGB1 | P05556 | 8/20 | 0.69 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.56 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.56 |
| ▸ | ITGAV | P06756 | 1/20 | 0.56 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.54 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7607529 | 0.90 | ITGA4 (0.59) | ITGA4ITGB1ITGA5ITGB3ITGAV | |
| SCHEMBL7607352 | 0.89 | ITGA4 (0.55) | ITGA4ITGB1ITGA5ITGB3ITGAV | |
| SCHEMBL6515404 | 0.87 | ITGB1 (0.65) | ITGA4ITGB1ITGA5ITGB3ITGAV | |
| SCHEMBL7605621 | 0.84 | GPR132 (0.60) | ITGA4ITGB1GPR132 | |
| SCHEMBL7605500 | 0.84 | ITGB1 (0.60) | ITGA4ITGB1ITGA5ITGB3ITGAV | |
| SCHEMBL7608108 | 0.83 | ITGA4 (0.55) | ITGA4ITGB1ITGA5ITGB3ITGAV | |
| SCHEMBL7612266 | 0.81 | ITGA4 (0.60) | ITGA4ITGB1ITGA5ITGB3ITGAV | |
| SCHEMBL7607524 | 0.81 | ITGA4 (0.51) | ITGA4ITGB1ITGA5ITGB3ITGAV | |
| SCHEMBL7709504 | 0.81 | ITGB1 (0.55) | ITGA4ITGB1ITGA5GPR132 | |
| SCHEMBL6516795 | 0.80 | ITGA4 (0.66) | ITGA4ITGB1ITGA5ITGB3ITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020035127-A1 | Phenylalanine derivatives | CELLTECH THERAPEUTIS, LIMITED | 2002-03-21 | — | — | US | disclosed |
| US-6329372-B1 | HETEROCYCLIC AMIDE COMPOUNDS ARE ABLE TO INHIBIT THE BINDING OF ALPHA4 INTEGRINS TO THEIR LIGANDS AND ARE OF USE IN THE PROPHYLAXIS AND TREATMENT OF IMMUNE OR INFLAMMATORY DISORDERS. | CELLTECH THERAPEUTICS LIMITED (GB) | 2001-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035127-A1 | Phenylalanine derivatives | PAH, VCAM1, IL4I1 | ITGA4 5/4885ITGB1 8/4885ITGA5 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.